Side-branch expansion capacity of contemporary DES platforms

Eur J Med Res. 2021 Oct 12;26(1):121. doi: 10.1186/s40001-021-00595-7.

Abstract

Background: Percutaneous coronary interventions (PCI) of bifurcation stenoses are both complex and challenging. Stenting strategies share that the stents' side cells must be carefully explored and appropriately prepared using balloons or stents. So far, stent manufacturers have not provided any information regarding side-branch expansion capacity of their stent platforms.

Aims: Given that drug-eluting stent (DES) information regarding their mechanical capacity of side-branch expansion is not available, we aimed to evaluate contemporary DES (Orsiro, BIOTRONIK AG; Xience Sierra, Abbott Vascular; Resolute Integrity, Medtronic; Promus Premier Select, Boston Scientific; Supraflex Cruz, Sahajan and Medical Technologies) by their side-branch expansion behavior using in vitro bench testing.

Methods: In this in vitro study, we analyzed five commercially available DES (diameter 3.0 mm), measuring their side-branch expansion following inflation of different high-pressure non-compliant (NC) balloons (balloon diameter: 2.00-4.00 mm), thereby revealing the morphological characteristics of their side-branch expansion capacities.

Results: We demonstrated that all tested contemporary DES platforms could withstand large single-cell deformations, up to 4.0 mm. As seen in our side-branch experiments, DES designs consisting of only two connectors between strut rings did not only result in huge cell areas, but also in larger cell diameters following side-branch expansion compared with DES designs using three or more connectors. Furthermore, the stent cell diameter attained was below the balloon diameter at normal pressure.

Conclusions: We recommend that the expansion capacity of side-branches should be considered in stent selection for bifurcation interventions.

Keywords: Bench test; Bifurcation; Mechanical load; Recoil.

MeSH terms

  • Drug Carriers / chemistry
  • Drug Carriers / standards*
  • Drug-Eluting Stents / standards*
  • Humans
  • Percutaneous Coronary Intervention / methods*

Substances

  • Drug Carriers